FDA Approval Activities for this Drug…

ADRIAMYCIN PFS (doxorubicin hydrochloride injection), Pharmacia & Upjohn Company NDA 50-467/S-064/S-067 & 50-629/S-010/S-013 Doxil (doxorubicin HCl liposome) Injection, ALZA NDA 50-718/S-016 12/17/02 Doxil (doxorubicin HCl liposome) Injection, ALZA NDA 50-718/S-010 1/10/02 2/8/02 Doxil (doxorubicin HCl liposome) Injection, 50 mg/m2, ALZA NDA 50-718/S-006 6/28/99 6/30/99 6/30/99 Doxil Injection: treatment of metastatic carcinoma of the ovary in patients with disease that is refractory to both paclitaxel- and platinum-based chemotherapy regimens. Doxorubicin Hydrochloride Injection, 10, 20, 50, and 150 & 10, 20, 50, 75, 150, and 200 mg, Pharmacia & Upjohn Company NDA 50-467/S-068/S-069 & 50-629/S-014/S-016 | Doxil (doxorubicin HCl liposome) injection, Johnson & Johnson Pharma, Efficacy Supplement with Clinical Data to Support | Doxil (doxorubicin HCl liposome injection), Alza Corp, Accelerated Approval | Doxil (Doxorubicin HCI Liposomal Injection), Alza Corp., Accelerated Approval

For the latest approval information, please locate this drug using this index.